Navigation Links
Amylin Announces Preliminary Tabulation of Annual Meeting Results
Date:6/2/2009

SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that IVS Associates, Inc., the independent Inspector of Elections for the Company's Annual Meeting of Stockholders held May 27, 2009, has completed its preliminary tabulation of shareholder votes. The preliminary tabulation indicates that shareholders voted to re-elect eight of the Company's current Directors to Amylin's Board of Directors - Adrian Adams, Steven R. Altman, Teresa Beck, Daniel M. Bradbury, Karin Eastham, Dr. James R. Gavin III, Dr. Jay S. Skyler, and Joseph P. Sullivan, as well as voted to elect its two new independent nominees, Paul N. Clark and Paulo F. Costa. In addition, Dr. Kathleen Behrens and Dr. Alexander J. Denner, Director candidates nominated by Eastbourne Capital Management, L.L.C. and Carl Icahn, respectively, were also elected to the Board. Joseph C. Cook, Jr., Amylin's Chairman, and James N. Wilson, Amylin's Lead Independent Director, were not re-elected to the Board.

Separately, IVS also reported the preliminary tabulation of the other proposals voted on at the Annual Meeting:

  • Approval of the Company's 2009 Equity Incentive Plan.
  • Approval of an increase of 1,500,000 shares in the aggregate number of shares of the Company's common stock authorized for issuance under the Company's 2001 Employee Stock Purchase Plan.
  • Ratification of the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2009.
  • Rejection of Mr. Icahn's proposal to change the Company's jurisdiction of incorporation from Delaware to North Dakota.

The Company issued the following statement:

       We thank all our shareholders for their support and greatly appreciate
       the valuable insights offered to our Board and management team.  We are
       also grateful for the significant contributions and guidance provided
       by outgoing Directors Joe Cook and Jim Wilson.  Their industry
       knowledge, expertise and leadership have been important assets to
       Amylin over their many years of service, and we wish them well in their
       future endeavors.

       All of us at Amylin remain deeply committed to building long-term value
       for all of our shareholders, especially through the anticipated launch
       of exenatide once weekly, our investigational therapy that has the
       potential to significantly advance the treatment of type 2 diabetes.
       We look forward to working with all our new Directors to bring
       transformational medicines to patients and to drive sustainable and
       profitable growth.

Voting results on Director elections and all proposals will be finalized once they are certified by the Inspector following a customary review and challenge period. A final tally of the votes will be published in the Company's next quarterly report on Form 10-Q which will be filed with the Securities and Exchange Commission in August.

About Amylin

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.

Forward Looking Statements

This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. Our actual results could differ materially from those discussed herein due to a number of risks and uncertainties, including risks that BYETTA, SYMLIN or exenatide once weekly may be affected by competition, unexpected new data, safety and technical issues, or manufacturing and supply issues; risks that our clinical trials will not be completed when planned, may not replicate previous results or achieve desired end-points; risks that our preclinical studies may not be predictive; risks that our NDAs for product candidates or sNDAs for label expansion requests may not be submitted timely or receive FDA approval; and other risks inherent in the drug development and commercialization process. Commercial and government reimbursement and pricing decisions and the pace of market acceptance may also affect the potential for BYETTA, SYMLIN or exenatide once weekly. These and additional risks and uncertainties are described more fully in the Company's most recently filed Form 10-Q. Amylin disclaims any obligation to update these forward-looking statements.

    CONTACTS:

    Alice Izzo
    Executive Director, Corporate Affairs
    Amylin Pharmaceuticals, Inc.
    (858) 642-7272
    alice.izzo@amylin.com

    or

    Steve Frankel / Averell Withers
    Joele Frank, Wilkinson Brimmer Katcher
    (212) 355-4449


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amylin Pharmaceuticals to Webcast First Quarter Results
10. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
11. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
Breaking Biology Technology:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
Breaking Biology News(10 mins):